Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05874999
Other study ID # COPD-HIIT ACUTE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 7, 2022
Est. completion date December 22, 2022

Study information

Verified date June 2023
Source Umeå University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system. The aims of this cross-over trial is: 1. To compare the acute effects of short-duration supramaximal high-intensity interval training (HIIT) vs. traditional moderate-intensity continuous training (MICT) in people with COPD and matched healthy controls (HC). 2. To investigate the feasibility of supramaximal HIIT in people with COPD and matched HC. 3. To compare the cardiorespiratory demand, exercise intensity and symptoms during a modified Borg Cycle Strength Test (BCST) and a cardiopulmonary exercise test (CPET) in people with COPD and HC.


Description:

In this study, eligible participants attended the facility four times within 14 days with at least 48 hours of rest between visits. Exercise tests (visit 1, week 1): After pulmonary functions tests, a CPET on a stationary bicycle was performed according to international guidelines. After 1.5 hours of recovery, a BCST was performed to assess anaerobic exercise capacity and determine exercise intensities for supramaximal HIIT. Exercise sessions (visit 2 - week 1; visit 3 - week 2; visit 4 - week 2): The order of the two first exercise sessions (HIIT at 60% of MPO6 or MICT) on a stationary bicycle were randomized. The exercise session at HIIT at 80% of MPO6 was always the third exercise session. During all exercise sessions, blood collection was performed at baseline after a 15-minute seated rest. During HIIT, blood was collected immediately after, and 30 minutes after the 10-minute HIIT period. For MICT, blood was collected after 10 minutes (isotime in relation to HIIT), immediately after, and 30 minutes of cycling at 60% MAP.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 22, 2022
Est. primary completion date December 22, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility COPD Inclusion Criteria: - COPD with non-reversible airflow obstruction diagnosis (post-bronchodilator forced expiratory volume during the first second/forced vital capacity (FEV1/FVC) < 0.7) - Age: > 40 years Exclusion Criteria: - Recent exacerbation of COPD (< 6 weeks) - Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing - Recent lung cancer (< 5 years) - Unstable cardiac disease and/or cardiac stimulator HC Inclusion Criteria: - Age: > 40 years Exclusion Criteria: - Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing - Any respiratory disease - Recent lung cancer (< 5 years) - Unstable cardiac disease and/or cardiac stimulator - Too low or high physical activity level that prohibits matching

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Supramaximal High-Intensity Interval Training at 60% of MPO6
Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle.
Moderate-Intensity Continuous Training
MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle. Duration MICT: 20 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle.
Supramaximal High-Intensity Interval Training at 80% of MPO6
Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST. Duration supramaximal HIIT: 10 minutes Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle.

Locations

Country Name City State
Sweden Umeå University Umeå

Sponsors (4)

Lead Sponsor Collaborator
Umeå University Riksförbundet HjärtLung, Swedish Heart Lung Foundation, The Swedish Research Council

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise intensity Produced watt at the set training intensity During visit 2 (week 1)
Primary Exercise intensity Produced watt at the set training intensity During visit 3 (week 2)
Primary Exercise intensity Produced watt at the set training intensity During visit 4 (week 2)
Primary Brain-derived neurotrophic factor (BDNF) Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. During visit 2 (week 1)
Primary Brain-derived neurotrophic factor (BDNF) Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. During visit 3 (week 2)
Primary Brain-derived neurotrophic factor (BDNF) Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. During visit 4 (week 2)
Secondary Cardiorespiratory demand Gas exchange parameters (e.g. VO2, VCO2, ventilatory equivalents, RER) and lung volumes (e.g. VE, Vt, breathing frequency) obtained with a metabolic cart (breath by breath methodology) and heart rate (beats per minutes) during exercise during exercise. During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Venous blood lactate concentration Measured before, during and after exercise. During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Rating of perceived exertion Rating of perceived exertion scale (Borg RPE). Minimum value = 6 Maximum value = 20 A higher score means higher exertion. During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Rating of symptoms Rating of dyspnea and leg fatigue symptoms via Borg CR (category ratio) 10 during exercise Minimum value = 0 Maximum value = 10 A higher score means higher severity of symptoms During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Peripheral blood oxygen saturation (SpO2) SpO2 during exercise During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Blood pressure Systolic and diastolic blood pressure during exercise During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Circulating levels of neurotrophic factors Plasma or serum concentration (measured as mg/l, ng/l, or pq/l) of irisin, cathepsin B, clusterin, in obtained venous blood samples before, during and after exercise. During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Circulating levels of exerkines Plasma or serum concentration of interleukin (IL)-1b, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17, tumor necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and adiponectin in obtained venous blood samples before, during and after exercise. During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Exercise session completion Number of uninterrupted exercise sessions During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Exercise preference Preference for HIIT at 60% of MPO6 or MICT, defined as answer on the following question:
"If the MICT and HIIT would be equally effective in improving your health and physical capacity, which one would you prefer to perform?"
At the end of visit 3 (week 2)
Secondary Session RPE Rating of session RPE on Borg CR (category ratio) 10 is assessed 30 min after every exercise session Minimum value = 0 Maximum value = 10 A higher score means higher session exertion During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
Secondary Exercise capacity Maximal aerobic power (MAP) expressed as produced watt at VO2peak During visit 1 (CPET; week 1)
Secondary Exercise intensity Maximum mean power output for 30 seconds (MPO30) in watts During visit 1 (BCST; week 1)
Secondary Adverse events Occurence and severity of adverse events. The severity of adverse events will be assessed and rated into four different categories: 1) minor and temporary, 2) serious symptoms (potential risk of severe injury or life threatening, 3) manifest injury or disease and 4) death. An adverse event rate will be calculated for each participant as the total number of sessions during which any adverse events occurred divided by the total number of attended sessions. During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A